GVHD Clinical Trial
Official title:
The Study of Anti-CD25 Antibody for Prophylaxis of GVHD in Patients Underwent Haploid Transplantation Conditioning With Low-dose ATG
The risk of Graft-versus-host Disease(GVHD) is significantly associated with the mortality rate of patients undergoing allogeneic hematopoietic stem cell transplantation. The occurrence of GVHD increases the hospitalization rate and economic burden of patients. In order to explore better methods for controlling GVHD, we designed a clinical trial using CD25 monoclonal antibody for GVHD prevention. Our previous studies have shown that reduced-dose anti-thymocyte globulin(ATG) in the conditioning regimen can achieve the same effect as full-dose ATG. Here, we try to explore the preventive effect of CD25 antibody on acute and chronic GHVD under low-dose ATG pretreatment condition.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02942173 -
CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT
|
Phase 2/Phase 3 | |
| Completed |
NCT02066051 -
IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD
|
N/A | |
| Terminated |
NCT01940796 -
Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)
|
Phase 1 | |
| Not yet recruiting |
NCT05544448 -
In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases
|
N/A | |
| Completed |
NCT01295710 -
Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)
|
Phase 3 | |
| Not yet recruiting |
NCT06075225 -
MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib
|
Phase 2 | |
| Not yet recruiting |
NCT06000982 -
Comparison of Different Dose of Post-transplantation Cyclophosphamide as Graft Versus Host Disease Prophylaxis
|
Phase 3 | |
| Active, not recruiting |
NCT03680092 -
Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation
|
Phase 2 | |
| Not yet recruiting |
NCT06083129 -
Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor
|
Phase 3 | |
| Not yet recruiting |
NCT05094765 -
Fecal Microbiota Transplant (FMT) Capsule for Improving the Efficacy of GI-aGVHD
|
Early Phase 1 | |
| Active, not recruiting |
NCT05415410 -
Proof-of-concept Trial of Apraglutide in GVHD
|
Phase 2 | |
| Completed |
NCT02441075 -
70% Ethanol for Decontamination of CVL Exposed to Calcineurine Inhibitors Version 1.0, 1/9/2014
|
N/A | |
| Completed |
NCT02588339 -
Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention
|
Phase 2 | |
| Completed |
NCT03846479 -
Itacitinib for Low Risk GVHD
|
Phase 2 | |
| Completed |
NCT02891603 -
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
|
Phase 1/Phase 2 | |
| Completed |
NCT02712762 -
Ocular Surface Disease in Chronic Graft-Versus-Host Disease (GVHD) Patients
|
||
| Completed |
NCT03945591 -
High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
|
Phase 2 | |
| Not yet recruiting |
NCT06411184 -
Safety and Efficacy of Treg Cell in the Treatment of GVHD
|
Phase 1/Phase 2 | |
| Terminated |
NCT02338232 -
Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation
|
N/A | |
| Completed |
NCT02156479 -
Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Allo-HSCT Recipients
|